keyword
MENU ▼
Read by QxMD icon Read
search

Uterine serous cancer

keyword
https://www.readbyqxmd.com/read/29703236/high-grade-serous-carcinoma-with-discordant-p53-signature-report-of-a-case-with-new-insight-regarding-high-grade-serous-carcinogenesis
#1
Yuichiro Hatano, Shinya Fukuda, Hiroshi Makino, Hiroyuki Tomita, Ken-Ichirou Morishige, Akira Hara
BACKGROUND: Although p53 signature, benign-appearing epithelial cells with p53 diffuse expression, is frequently found in the fallopian tubes, the clinical and pathological significance of this lesion in the case of high-grade serous carcinoma (HGSC) patients still remains unclear. CASE PRESENTATION: A 56-year-old woman was referred to the gynecologist on account of abdominal distention. Since radiological and serological workup suggested that her illness was due to advanced ovarian cancer (FIGO Stage IVB), she received neoadjuvant chemotherapy, and the clinical evaluation of the chemotherapeutic response was a partial response...
April 27, 2018: Diagnostic Pathology
https://www.readbyqxmd.com/read/29675469/noninvasive-ovarian-cancer-biomarker-detection-via-an-optical-nanosensor-implant
#2
Ryan M Williams, Christopher Lee, Thomas V Galassi, Jackson D Harvey, Rachel Leicher, Maria Sirenko, Madeline A Dorso, Janki Shah, Narciso Olvera, Fanny Dao, Douglas A Levine, Daniel A Heller
Patients with high-grade serous ovarian carcinoma (HGSC) exhibit poor 5-year survival rates, which may be significantly improved by early-stage detection. The U.S. Food and Drug Administration-approved biomarkers for HGSC-CA-125 (cancer antigen 125) and HE4 (human epididymis protein 4)-do not generally appear at detectable levels in the serum until advanced stages of the disease. An implantable device placed proximal to disease sites, such as in or near the fallopian tube, ovary, uterine cavity, or peritoneal cavity, may constitute a feasible strategy to improve detection of HGSC...
April 2018: Science Advances
https://www.readbyqxmd.com/read/29671892/frequent-loss-of-claudin-4-expression-in-dedifferentiated-and-undifferentiated-endometrial-carcinomas
#3
Basile Tessier-Cloutier, Robert A Soslow, Colin J R Stewart, Martin Köbel, Cheng-Han Lee
INTRO: Dedifferentiated/undifferentiated endometrial carcinomas (DDEC/UEC) are aggressive endometrial cancers with frequent genomic inactivation of core components of switch/sucrose non-fermentable (SWI/SNF) complex proteins. Claudin-4, an epithelial intercellular tight junction protein was recently found to be expressed in SWI/SNF-deficient undifferentiated carcinomas but not SWI/SNF-deficient sarcomas. The aim of this study is to examine claudin-4 expression in UEC/DDEC and other high-grade uterine carcinomas...
April 19, 2018: Histopathology
https://www.readbyqxmd.com/read/29584549/randomized-phase-ii-trial-of-carboplatin-paclitaxel-versus-carboplatin-paclitaxel-trastuzumab-in-uterine-serous-carcinomas-that-overexpress-human-epidermal-growth-factor-receptor-2-neu
#4
Amanda N Fader, Dana M Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko K Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M O'Malley, Floor Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim S ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E Schwartz, Alessandro D Santin
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease...
March 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29572834/impact-of-brca-mutations-on-outcomes-among-patients-with-serous-endometrial-cancer
#5
Yfat Kadan, Oshrat Raviv, Yakir Segev, Ofer Lavie, Ilan Bruchim, Ami Fishman, Rachel Michaelson, Uzi Beller, Limor Helpman
OBJECTIVE: To compare the outcome of patients with uterine papillary serous cancer (UPSC) carrying a BRCA mutation with that of patients with UPSC who are BRCA wild-type. METHODS: The present retrospective, multicenter cohort study included women with UPSC who were diagnosed between January 1, 1993, and December 31, 2014, and were tested for the BRCA mutation at three Israeli medical centers. Data were collected from the medical records, and patient and tumor characteristics and disease outcomes were compared between BRCA mutation carriers and noncarriers...
March 23, 2018: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/29565096/aging-and-uterine-serous-carcinoma
#6
REVIEW
Toru Hachisuga
Uterine serous carcinoma (USC) is closely associated with advanced age in patients. The p53 signature (p53S) is considered the earliest indication for the presence of carcinogenesis of USC. Based on our previous studies, the presence of p53Ss have almost always been found in elderly women and are suspected of being responsible for the imbalance between the proliferation and apoptosis of endometrial epithelial cells with advanced age. We have summarized the current state of knowledge regarding the association between age and cancer and propose an age-related type of endometrial cancer instead of Type II estrogen-independent endometrial cancer...
March 22, 2018: Histology and Histopathology
https://www.readbyqxmd.com/read/29544706/the-role-of-adjuvant-therapy-in-stage-ia-serous-and-clear-cell-uterine-cancer-a-multi-institutional-pooled-analysis
#7
X Melody Qu, Vikram M Velker, Eric Leung, Janice S Kwon, Mohamed A Elshaikh, Iwa Kong, Natalie A Logie, Lucas C Mendez, Louis J van der Putten, Elysia K Donovan, Adnan R Munkarah, Ericka M Wiebe, Carlos Parra-Herran, Andrew Warner, Alexander V Louie, David P D'Souza
OBJECTIVE: As the optimal adjuvant management of stage IA serous or clear cell endometrial cancer is controversial, a multi-institutional review was conducted with the objective of evaluating the appropriateness of various strategies including observation. METHODS: Retrospective chart reviews for 414 consecutive patients who underwent hysterectomy for FIGO stage IA endometrial cancer with serous, clear cell or mixed histology between 2004 and 2015 were conducted in 6 North American centers...
May 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29533019/prognostic-factors-for-patients-with-early-stage-uterine-serous-carcinoma-without-adjuvant-therapy
#8
Keisei Tate, Hiroshi Yoshida, Mitsuya Ishikawa, Takashi Uehara, Shun Ichi Ikeda, Nobuyoshi Hiraoka, Tomoyasu Kato
OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive type 2 endometrial cancer. Data on prognostic factors for patients with early-stage USC without adjuvant therapy are limited. This study aims to assess the baseline recurrence risk of early-stage USC patients without adjuvant treatment and to identify prognostic factors and patients who need adjuvant therapy. METHODS: Sixty-eight patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-II USC between 1997 and 2016 were included...
May 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29518404/microrna-signatures-discriminate-between-uterine-and-ovarian-serous-carcinomas
#9
Pei Hui, Stefan M Gysler, Mohamed Uduman, Taiwo A Togun, Daniel E Prado, Christine E Richter, Sunitha Nallur, Peter E Schwartz, Thomas J Rutherford, Alessandro D Santin, Joanne B Weidhaas, Elena S Ratner
Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy. When a high-grade serous carcinoma concurrently involves both ovary and endometrium, pathological determination of whether they are synchronous primaries or metastatic tumors from one primary site can be challenging. MicroRNAs (miRNA) are 22-nucleotide noncoding RNAs that are aberrantly expressed in cancer cells and may inherit their cellular linage characteristics...
March 5, 2018: Human Pathology
https://www.readbyqxmd.com/read/29477660/moving-forward-with-actionable-therapeutic-targets-and-opportunities-in-endometrial-cancer-a-nci-clinical-trials-planning-meeting-report
#10
REVIEW
Stephanie Lheureux, Carolyn McCourt, B J Rimel, Linda Duska, Gini Fleming, Helen Mackay, David Mutch, Sarah M Temkin, Jean Lynn, Elise C Kohn
The incidence of endometrial cancer (EC) in the U.S. has been rising, from an estimated annual incidence of 49,560 in 2013 to 61,380 in 2017. Meanwhile, the SEER-based relative survival of women with EC in the U.S. has remained flat [82.3% from 1987 to 1989, 82.8% from 2007 to 2013] and our recent increased understanding of EC biology and subtypes has not been translated into therapeutic advances. The U.S. National Cancer Institute (NCI) therefore convened a Uterine Clinical Trials Planning Meeting in January 2016 to initiate and accelerate design of molecularly-targeted EC trials...
February 22, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29440294/-in-vitro-and-in-vivo-activity-of-imgn853-an-antibody-drug-conjugate-targeting-folate-receptor-alpha-linked-to-dm4-in-biologically-aggressive-endometrial-cancers
#11
Gary Altwerger, Elena Bonazzoli, Stefania Bellone, Tomomi Egawa-Takata, Gulden Menderes, Francesca Pettinella, Anna Bianchi, Francesco Riccio, Jacqueline Feinberg, Luca Zammataro, Chanhee Han, Ghanshyam Yadav, Katherine Dugan, Ashley Morneault, Jose F Ponte, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Gloria S Huang, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
Grade 3 endometrioid and uterine serous carcinomas (USC) account for the vast majority of endometrial cancer deaths. The purpose of this study was to determine folic acid receptor alpha (FRα) expression in these biologically aggressive (type II) endometrial cancers and evaluate FRα as a targetable receptor for IMGN853 (mirvetuximab soravtansine). The expression of FRα was evaluated by immunohistochemistry (IHC) and flow cytometry in 90 endometrioid and USC samples. The in vitro cytotoxic activity and bystander effect were studied in primary uterine cancer cell lines expressing differential levels of FRα...
May 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29393245/serous-carcinoma-of-the-uterine-cervix-an-extremely-rare-aggressive-entity-a-literature-review
#12
Joanna Jonska-Gmyrek, Agnieszka Zolciak-Siwinska, Leszek Gmyrek, Wojciech Michalski, Grazyna Poniatowska, Malgorzata Fuksiewicz, Pawel Wiechno, Jakub Kucharz, Maria Kowalska, Beata Kotowicz
BACKGROUND/AIMS: Serous carcinoma of the uterine cervix (USCC) is an extremely rare subtype. To establish the treatment strategy in patients with USCC is an important issue. METHODS: MEDLINE (PubMed) was searched for all articles published after the first publication by Lurie et al. [Eur J Obstet Gynecol Reprod Biol 1991; 40: 79-81], reporting woman diagnosed with USCC. Because of limited numbers of studies on the topic of the study, we could not keep a restriction of eliminating smaller sample sizes...
January 23, 2018: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/29303934/calcification-a-disregarded-or-ignored-issue-in-the-gynecologic-tumor-microenvironments
#13
Jirui Wen, Yali Miao, Shichao Wang, Ruijie Tong, Zhiwei Zhao, Jiang Wu
Although calcification in the gynecologic tumor microenvironments is a common phenomenon, doctors and researchers still disregard or ignore the issue. In fact, this change in the gynecologic tumor microenvironments is clinically significant and a number of studies have reported an association between calcification and gynecological tumor progression. In ovarian cancer, calcification is predominantly psammomatous and largely occurs in serous papillary ovarian tumors. In addition, calcification in ovarian cancer correlated with lower histologic grade and may indicate a poorer survival rate...
March 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29290193/spectrum-of-gynecological-malignancies-at-jamshoro
#14
Naheed Parveen, Raheel Sikander, Majida, Shaheen
OBJECTIVE: To describe the frequency and spectrum of different types of gynecological malignancies. STUDY DESIGN: An observational study. PLACE AND DURATION OF STUDY: Department of Obstetrics and Gynaecology, Liaquat University of Medical and Health Sciences, Jamshoro, from January 2014 to December 2015. METHODOLOGY: All patients with gynecological malignancies, admitted at the study place, whether previously diagnosed or need to establish the diagnosis on the basis of EUA, biopsy, staging and for surgery during the study period were included...
January 2018: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29234950/the-evolution-of-endometrial-carcinoma-classification-through-application-of-immunohistochemistry-and-molecular-diagnostics-past-present-and-future
#15
REVIEW
Emily A Goebel, August Vidal, Xavier Matias-Guiu, C Blake Gilks
Uterine cancer was first subclassified based on anatomic site, separating those tumours arising from the endometrium from cervical cancers. There was then further subclassification of endometrial cancers based on cell type, and this correlated with the Type I and Type II categories identified through the epidemiological studies of Bokhman, with endometrioid carcinoma corresponding (approximately) to Type I and serous carcinoma to Type II. These histotypes are not clearly separable in practice, however, with considerable interobserver variability in histotype diagnosis, especially for high-grade tumours...
December 12, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29206664/chemoresistance-of-gastric-type-mucinous-carcinoma-of-the-uterine-cervix-a-study-of-the-sankai-gynecology-study-group
#16
Atsumi Kojima, Muneaki Shimada, Yoshiki Mikami, Shoji Nagao, Nobuhiro Takeshima, Toru Sugiyama, Norihiro Teramoto, Takako Kiyokawa, Junzo Kigawa, Ryuichiro Nishimura
OBJECTIVE: Gastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine cervix, characterized by aggressive clinical behavior and absence of high-risk human papillomavirus. We conducted this study to evaluate the chemosensitivity of GAS compared with that of usual-type endocervical adenocarcinoma (UEA) in patients who had been enrolled in our previous study. METHODS: Of 52 patients from our previous phase 2 study (SGSG005) of neoadjuvant chemotherapy with docetaxel and carboplatin for stage IB2 to IIB nonsquamous cervical cancer, 47 (stage IB2, 12; stage IIA2, 7; stage IIB, 28) were enrolled in this study with written informed consent...
January 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29203914/synthetically-lethal-nanoparticles-for-treatment-of-endometrial-cancer
#17
Kareem Ebeid, Xiangbing Meng, Kristina W Thiel, Anh-Vu Do, Sean M Geary, Angie S Morris, Erica L Pham, Amaraporn Wongrakpanich, Yashpal S Chhonker, Daryl J Murry, Kimberly K Leslie, Aliasger K Salem
Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies...
January 2018: Nature Nanotechnology
https://www.readbyqxmd.com/read/29130934/recurrent-ubiquitin-b-silencing-in-gynecological-cancers-establishes-dependence-on-ubiquitin-c
#18
Alexia T Kedves, Scott Gleim, Xiaoyou Liang, Dennis M Bonal, Frederic Sigoillot, Fred Harbinski, Sneha Sanghavi, Christina Benander, Elizabeth George, Prafulla C Gokhale, Quang-De Nguyen, Paul T Kirschmeier, Robert J Distel, Jeremy Jenkins, Michael S Goldberg, William C Forrester
Transcriptional repression of ubiquitin B (UBB) is a cancer-subtype-specific alteration that occurs in a substantial population of patients with cancers of the female reproductive tract. UBB is 1 of 2 genes encoding for ubiquitin as a polyprotein consisting of multiple copies of ubiquitin monomers. Silencing of UBB reduces cellular UBB levels and results in an exquisite dependence on ubiquitin C (UBC), the second polyubiquitin gene. UBB is repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is a recurrent lesion in uterine carcinosarcoma and endometrial carcinoma...
December 1, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29113150/aberrant-chromatin-remodeling-in-gynecological-cancer
#19
Ryuichiro Okawa, Kouji Banno, Miho Iida, Megumi Yanokura, Takashi Takeda, Moito Iijima, Haruko Kunitomi-Irie, Kanako Nakamura, Masataka Adachi, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Yusuke Kobayashi, Eiichiro Tominaga, Daisuke Aoki
Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich interactive domain-containing protein 1A (ARID1A) and SWItch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 are remodeling factors that are mutated in numerous types of cancer. In gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29037481/surgical-outcomes-among-elderly-women-with-endometrial-cancer-treated-by-laparoscopic-hysterectomy-a-nrg-gynecologic-oncology-group-study
#20
Erin A Bishop, James J Java, Kathleen N Moore, Nick M Spirtos, Michael L Pearl, Oliver Zivanovic, David M Kushner, Floor Backes, Chad A Hamilton, Melissa A Geller, Jean Hurteau, Cara Mathews, Robert M Wenham, Pedro T Ramirez, Susan Zweizig, Joan L Walker
OBJECTIVE: Tolerance of and complications caused by minimally invasive hysterectomy and staging in the older endometrial cancer population is largely unknown despite the fact that this is the most rapidly growing age group in the United States. The objective of this retrospective review was to compare operative morbidity by age in patients on the Gynecologic Oncology Group Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus (LAP2) trial...
January 2018: American Journal of Obstetrics and Gynecology
keyword
keyword
16962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"